Interestingly, very recent analyses have revealed the presence of focal tandem duplications in many other cancers with a low incidence (<2%) of CDK12 inactivation (96), suggesting their occurrence in addition to ovarian and prostate cancers. This evidence concerns the gene CDK12 and cancer.